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Abstract Interleukin (IL)-6 is a multifactorial cytokine
known to be increased in patients with chronic hepatitis C
(CHC) and to be predictive of depression incidence. The
aim of the study was to explore the association between IL6
gene C-174G polymorphism and depressive symptom
severity in the longitudinal study design following the
course of pegylated interferon/ribavirin treatment in CHC
patients. In our study, we included 62 CHC subjects. They
were assessed using present state examination, Beck
Depression Inventory (BDI) and Montgomery A˚sberg
Depression Rating Scale (MADRS) at weeks 0, 3, 5, 9, 13,
24 and 24 weeks after the end of treatment. The risk of
depression was associated with higher baseline MADRS
score and BDI score. Interestingly, when stratified by IL6
C-174G polymorphism, higher baseline depressive symp-
tom severity measured by MADRS and BDI predicted
higher risk of depression in the course of antiviral treat-
ment only in high IL-6 producers—G allele carriers
(patients with GG and CG genotypes) (p = 0.004,
p = 0.00008, respectively). There is interaction between
severity of baseline depressive symptoms at the beginning
of antiviral therapy and IL6 gene C-174G polymorphism
leading to increased risk for the development of depressive
episode in CHC patients in the course of antiviral
treatment.
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Abbreviation
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CHC Chronic hepatitis C
IFN-a Interferon a
BDI Beck Depression Inventory
PSE Present state examination
MADRS Montgomery A˚sberg Depression Rating Scale
IL-6 Interleukin 6
Introduction
Interferon (IFN)-a is the main pharmacological treat-
ment for chronic hepatitis C virus (HCV) infection,
because of its potent antiviral, antiproliferation and
immunomodulatory properties (Lamers et al. 2012);
however, at the same time IFN-a is known to induce
several neuropsychiatric side effects, including anorexia,
fatigue, lethargy, loss of interest, lack of concentration,
irritability, cognitive decline, emotional lability and
social withdrawal (Cattie et al. 2014). Depression is a
particularly common side effect and in some rare cases
may be associated with deliberate self-harm or suicide
attempts. Thus, identification of risk factors that lead to
depression may help to recognize patients at risk who
may benefit from additional psychological support
(Smith et al. 2011).
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IFN-a induces depression, but only in a subset of
patients (Capuron et al. 2002; Lotrich et al. 2007; Mus-
selman et al. 2001) and several vulnerability factors that
predict depression after IFN-a treatment have been
described, such as: levels of circulating cytokines (Krueger
et al. 2011), brain-derived neurotrophic factor serum level
(Kenis et al. 2011), elevated ratio of arachidonic acid to
long-chain omega-3 fatty acids (Lotrich et al. 2013),
changes in serotoninergic system (Bonaccorso et al. 2002),
hypothalamic–pituitary–adrenal axis deregulation and
glucocorticoid resistance (Raison et al. 2010).
Most of the published genetic association studies of
mood disorders have focused on functional polymorphisms
in the loci encoding the serotonin transporter (SLC6A4),
serotonin 2A receptor (5HTR2A), tyrosine hydroxylase
(TH), tryptophan hydroxylase 1 (TPH1), and catechol-o-
methyltransferase (COMT); however, recent meta-analysis
of 183 papers that studied 393 polymorphisms in 102 genes
found significant evidence for association for the following
genes: APOE, DRD4, GNB3, MTHFR, SLC6A3 and
SLC6A4 (Lopez-Leon et al. 2008).
It has also been shown that biological mechanisms
responsible for IFN-a-induced depression can also be
influenced by underlying genetic vulnerability. Several
genetic polymorphisms have been analyzed to identify
increased risk factors for developing depression in the
course of IFN-a treatment, including serotonin transporter
gene (5-HTTLPR) (Bull et al. 2009), 5-HT1A receptor gene
(Kraus et al. 2007), tryptophan hydroxylase-2 gene (TPH2)
(Kraus et al. 2007), phospholipase A2 (PLA2) and
cyclooxygenase 2 (COX2) gene (Su et al. 2010). Addi-
tionally, with respect to immune system the following
genes have been analyzed: IFN-a/b receptor 1 (IFNAR1)
gene (Smith et al. 2012), IL-6 gene (IL6) (Bull et al. 2009;
Udina et al. 2013), IL-1 a and b (IL1A, IL1B) genes (Smith
et al. 2012), IFN-c (IFNG) gene (Oxenkrug et al. 2011) as
well as genes encoding IL28B (Pasha et al. 2013), TGF-b1
(Pasha et al. 2013) and TNF-a (Pasha et al. 2013). More-
over, recently 15 genes were identified that were
selectively hyper-responsive to exogenous IFN-a in
patients that developed depressive side effects (Schlaak
et al. 2012).
The majority of the studies focus on genetic vulnera-
bility to neuropsychiatric disturbances in the course of
IFN-a treatment based on the comparison between the
patients who developed depression with the non-depressed
group. However, little is known about the influence of
genetic polymorphisms on the symptom severity in the
longitudinal approach that allows for multiple assessment
of psychological functioning from the beginning to the end
of treatment in all patients undergoing treatment, and not
only patients who ultimately develop depression.
Materials and Methods
Subjects
We included 62 subjects in the study. All subjects had
chronic HCV infection with compensated liver disease.
Subjects were recruited from the Department of Infectious
Diseases, Hepatology and Acquired Immunodeficiencies
Medical University in Wroclaw, Poland. All subjects were
of Caucasian origin (31 females and 31 males of mean age
49.16 ± 10.73 and 33.55 ± 11.49, respectively). They
were entirely native unrelated Polish population recruited
from the same geographic area—Lower Silesia region. All
patients were receiving pegylated IFN-a2a (Pegasys;
Hoffmann-LaRoche, Basel, Switzerland) at a dose of
180 lg once per week. Additionally, they were receiving
ribavirin (Schering-Plough Corp) at a dose of 1000 mg per
day if their body weight was\75 kg or 1200 mg per day if
their body weight was C75 kg. The duration of treatment
was 48 weeks, except for patients infected with genotype 3
HCV who were treated for 24 weeks.
Patients having a history of traumatic brain injury or
neurologic disorders were excluded from the study by
detailed medical examination. Other exclusion criteria
included prior treatment with IFN-a therapy, pregnancy,
autoimmune disorder and any cause for liver disease other
than HCV infection. None of the participants were
receiving antidepressant or anxiety medications 6 months
prior to inclusion into the study. There were no subjects
addicted either to drugs or alcohol in our study sample. The
study was approved by the Institutional Ethics Committee
and all participants provided written informed consent
prior to participation.
Study Design
Subjects had a baseline psychiatric evaluation of mental
state and previous psychiatric history, using present state
examination (PSE) from Schedules of Clinical Assessment
in Neuropsychiatry (SCAN 2.0) performed by a senior
board-certified investigator. Categorical depressive episode
during therapy was diagnosed according to Diagnostic and
Statistical Manual IV Axis I Disorders. Additionally,
Montgomery A˚sberg Depression Rating Scale (MADRS)
and Beck Depression Inventory (BDI) were used to assess
the severity of depressive symptoms. The study followed a
prospective longitudinal cohort design. Subjects were
evaluated with PSE, MADRS and BDI before they started
treatment (week 0) and at weeks 3, 5, 9, 13 and 24, at the
end of treatment as well as 24 weeks after the end treat-
ment. At each assessment point blood samples were also
collected. Preliminary results on depressive symptoms
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during treatment with IFN-a for HCV infection have been
published previously (Malyszczak et al. 2006).
Genotyping
Genomic DNA was prepared from peripheral white blood
cells from whole frozen blood using the QIAamp DNA
Blood Mini Kit (Qiagen GmbH, Hilden, Germany). Single
nucleotide polymorphism in IL6 gene (rs1800795) was
genotyped by a single specific primer-polymerase chain
reaction using OneLambda commercial sets PCytgen. As a
quality control, we retyped 10% with allelic discrimination
methods using LightSNiP Assay on demand for rs1800975
(TIB MOLBIOL, Poznan, Poland).
Statistical Analysis
Demographic and clinical data among patients with and
without depressive episode in the course of antiviral
treatment were compared using ANOVA test (age, illness
duration, total IFN dose, total ribavirin dose, treatment
duration, number of copies of the HCV, grading/staging
of disease, TSH level) and v2 test (gender, HCV,
genotype, family history of psychiatric illness, past his-
tory of psychiatric illness). Evaluation of the Hardy–
Weinberg equilibrium (HWE) was performed by com-
paring the observed and expected genotype distribution
using the v2 goodness-of-fit test. Distribution of alleles
and genotypes of IL6 C-174G gene polymorphism was
assessed using v2 test. Differences between depression
severity assessed with MADRS and BDI scales at the
beginning of the treatment, during the treatment and
24 weeks after completion of treatment were compared
using paired samples t test. Severity of baseline depres-
sive symptoms measured with MADRS and BDI scales
with respect to the IL6 C-174G gene polymorphism was
compared using Mann–Whitney U test. Differences were
considered as statistically significant if the two-tailed
p value was less than 0.05. All analyses were performed
using the Statistical Package for Social Sciences version
20.
Results
In our study, we observed an inverted U-shaped curve of
depressive symptom severity in the course of antiviral
therapy (Fig. 1). There was a statistically significant dif-
ference between the depression severity at the beginning of
the treatment as assessed by MADRS and BDI
(6.39 ± 4.69 and 6.16 ± 5.557, respectively) and in the
course of treatment, calculated as mean value of depressive
symptoms in the course of treatment as assessed by
MADRS and BDI (12.78 ± 6.68 and 9.51 ± 7.49,
respectively; p\ 0.00001). The depressive symptoms were
diminished 24 weeks after the end of the treatment as
assessed by MADRS and BDI (5.37 ± 6.35 and
4.75 ± 7.76, respectively; p\ 0.0001) reaching the level
of depression assessed at the beginning of treatment by
MADRS and BDI (p = 0.25 and p = 0.11, respectively;
Fig. 1).
In our study, 24 patients (38.71%) developed depression
in the course of IFN-a and ribavirin therapy. Patients with
and without depressive episode did not differ in age, gen-
der, duration of illness, treatment parameters, virus
genotype, grading and staging of disease, TSH level
(p[ 0.05; Table 1) or family history of psychiatric disor-
ders (Table 2). However, we have found an association
between development of depressive episode in the course
of antiviral therapy and patients’ past psychiatric history of
depressive or anxiety disorder (Table 2).
The genotypic distribution of IL6 gene C-174G poly-
morphism was in HWE. There were also no differences in
the distribution of alleles or genotypes of IL6 gene poly-
morphism between these groups of patients (p[ 0.05;
Table 3). Depressive symptom severity assessed with
MADRS and BDI at the beginning of therapy were pre-
dictors of development of depressive episode during the
course of antiviral treatment (p = 0.00004, p = 0.00003,
respectively; Table 4). Interestingly, after stratifying
patients according to the IL6 gene C-174 gene polymor-
phism genotypes, we have shown that higher baseline
depressive symptom severity measured by MADRS and
BDI predicted higher risk of depression in the course of
antiviral treatment in G only allele carriers (patients with
GC and GG genotype) (p = 0.004, p = 0.00008, respec-
tively; Table 4).
Discussion
Anti-HCV treatment causes a dramatic increase in the
prevalence of depression, from 8% at the beginning to
38.71% in the middle of the treatment. The starting value
of depression prevalence is almost threefold more than in
the general population in Poland (3%) (Kiejna et al. 2015)
and similar to the prevalence among university students in
Wroclaw (9.8%) (Zagdanska and Kiejna 2016). The patient
population is more depressive than the general population,
so the prevalence difference between them is likely to be
demonstrated. The study showed that treatment resulted in
a significant increase not only in the symptoms, but also in
the prevalence of depression.
IFN-a-induced neuropsychiatric symptoms have been
attributed to the induction of pro-inflammatory cytokines
that modulate several neurophysiological and
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neuroendocrine systems involved in mood regulation
(Raison et al. 2006). IFN-a is a potent inducer of pro-
inflammatory cytokines, including IL-6. This cytokine
appears to play an important role in the development of
psychopathological side effects including depressive
symptoms as well as in viral response in the course of IFN-
a treatment (Guzman-Fulgencio et al. 2012).
In our study, we have shown that patients with past
history of depressive or anxiety disorders have higher risk
of developing depressive episode during antiviral therapy.
This result is in line with numerous studies on the general
population (Patten 2013) as well as with a recent meta-
analytic study on IFN-induced depression in CHC patients
(Udina et al. 2012). Additionally, we have shown the role
of baseline depressive symptom severity in the develop-
ment of depressive episode in patients receiving a
combination of pegylated IFN-a and ribavirin. This result
is in line with several previous studies showing the role of
sub-syndromal baseline symptoms in patients having
antiviral therapy (Dell’Osso et al. 2013; Mahajan et al.
2014).
A functional G[C single nucleotide polymorphism (C-
174G, rs1800795) in the promoter region of the IL6 gene is
associated with differential IL-6 expression and ultimately
IL-6 plasma concentrations. It has been shown that the G
allele is associated with higher plasma concentrations of
IL-6 during immune activation than the C allele (Fishman
et al. 1998). It has been shown that ‘‘high IL-6’’ genotype is
associated with more depressive symptoms during IFN-a
treatment in CHC patients (Bull et al. 2009; Udina et al.
2013). This finding is consistent with the evidence that
plasma IL-6 positively is associated with depressive
symptoms among patients without any immune-modula-
tory treatment (Liu et al. 2012) as well as among patients
during IFN-a treatment (Bonaccorso et al. 2001; Prather
et al. 2009; Wichers et al. 2007) including CHC patients
(Udina et al. 2012). Moreover, baseline psychopathological
symptom severity has been shown to predict mood epi-
sodes during CHC therapy (Dell’Osso et al. 2013; Rempel
et al. 2014). In our study we have shown that even though
IL6 C-174G gene polymorphism was not associated with
the risk of depression, there was an interaction between IL-
Fig. 1 Depressive symptoms
measured by MADRS and BDI
scales during treatment and after
24 weeks after the end of
treatment
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6 high producer G allele carriers and baseline depressive
symptoms, conferring together higher risk of depressive
episode in the course of antiviral treatment in CHC
patients. To the best of our knowledge, it is the first study
showing this effect.
According to a recent meta-analytic study, one in four
CHC patients who start IFN and ribavirin treatment
develop an induced depressive episode (Udina et al. 2012).
The results of our study point to the high importance of
detailed psychiatric evaluation of CHC patients subjected
to antiviral therapy, including past psychiatric history and
baseline depressive symptom severity, since these are risk
factors for the development of depressive episode in the
course of treatment and might influence treatment
outcome.
Our study has several limitations that need to be
addressed. First of all, there was a relatively small sample
size of our study group; however, it should be noted that
each patient was evaluated in detail at eight time points
over 48 weeks with not only PSE, but also MADRS and
BDI. However, the small number of subjects precluded us
from conducting further subgroup analyses, and therefore
we cannot exclude the effect of differences in the pattern of
use of psychotropic medications on depression scores.
Additionally, our findings should be approached with
caution, given the lack of concomitant biological measures,
such as plasma and cerebrospinal fluid concentrations of
IL-6. This might have enriched the results of our study,
Table 1 Demographic and clinical characteristics of the patients with respect to IFN-a-related depressive episode
Demographic and clinical variables Depressive episode in the course of treatment p value
No (n = 38) Yes (n = 24)
Age (years)a 47.79 ± 11.09 46.79 ± 11.80 0.73c
Gender [n (%)]
Males 18 (47.4%) 13 (54.2%) 0.60d
Females 20 (52.6%) 11 (45.8%)
Duration of illness (years)a 6.84 ± 4.06 7.42 ± 4.10 0.59c
Total interferon dose (mg)a 6640 ± 2113 6700 ± 2130 0.91c
Total ribavirin dose (mg)a 291505 ± 97937 281042 ± 102149 0.69c
Treatment duration (weeks)a 39.82 ± 11.81 38.71 ± 12.49 0.73c
HCV RNA (106 copies/mL)a 7.4 ± 8.80 14.85 ± 24.10 0.09c
TSH level at baseline (mIU/L)a 1.20 ± 1.19 1.77 ± 1.24 0.08d
Virus genotype
1 26 (68.5%) 16 (66.7%) 0.94d
3 11 (28.9%) 7 (29.1%)
4 1 (2.6%) 1 (4.2%)
Grading (Metavir scale)b 2.07 ± 0.68 (2) 1.91 ± 0.7 (2) 0.4e
Staging (Metavir scale)b 2.09 ± 0.70 (2) 1.75 ± 0.88 (1.5) 0.06e
a Mean ± standard deviation (SD)
b Mean ± SD (median)
c ANOVA test
d v2 test
e Mann–Whitney U test
Table 2 History of psychiatric disorders and baseline depressive
symptoms with respect to IFN-a-related depressive episode
Psychiatric
evaluation
Depressive episode in the course of
treatment
p valuea
No (n = 38) (%) Yes (n = 24) (%)
Family history of psychiatric disorder
None 22 (57.9) 14 (58.3) 0.85
Depression 4 (10.5) 2 (8.3)
Bipolar disorder 0 (0) 0 (0)
Schizophrenia 1 (2.6) 1 (4.2)
Anxiety disorder 2 (5.3) 1 (4.2)
Alcohol
dependence
8 (21.1) 5 (20.9)
Suicide 1 (2.6) 1 (4.2)
Past history of psychiatric disorders
None 32 (57.89) 14 (58.33) 0.038
Depression 5 (36.84) 4 (20.83)
Anxiety disorder 1 (5.26) 3 (12.5)
Suicide attempts 0 (0) 3 (8.33)
a v2 test
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since we would have been able to confirm as to whether G
allele carriers were indeed producing higher levels of IL-6
and assess the influence of IL-6 levels depressive symptom
severity and risk of depression episode development in the
course of antiviral treatment.
In conclusion, past psychiatric history and severity of
baseline depressive symptoms at the beginning of antiviral
therapy together with IL6 C-174G gene polymorphism may
serve as risk factors for the development of depressive
episode in CHC patients.
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